Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.
Congress in January approved a two-year suspension on the tax, which would be delayed to December 2024 under a wider tax package introduced Dec. 10 by Rep. Kevin Brady, chairman of the House Ways and Means Committee.
“While our membership, comprised of the nation’s leading medical technology innovators, certainly welcomes an additional 5-year reprieve from the tax, CLSA will continue to advocate for full and permanent repeal,” said Sara Radcliffe, president & CEO of California Life Sciences Association.
January’s vote was the second delay in the tax, first instituted in 2013 on artificial joints, heart stents and other devices to help fund the Affordable Care Act.
The House has previously voted to kill the tax, with the legislation dying in the Senate.
